Further assessment of the roles of resistin in patients with diabetes and myocardial I/R injury could improve the comprehension of the underlying pathways involved in the physiological and pathological development of the disease and potentially lead to improved treatment strategies for affected individuals. This evidence concerns the gene RETN and diabetes mellitus.